Key Highlights
- PDS Biotechnology shares closed up 35% at $0.40.
- The company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.
- A further $11.0 million milestone closing is tied to submission of a registrational Phase 3 PDS0301 protocol to the FDA.
- NantWorks receives a one-year exclusive negotiation right for PDS0101, and Dr. Patrick Soon-Shiong joins the board.
PDS Biotechnology Corporation (NASDAQ: PDSB) shares closed up 35% at $0.40 after the company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.
What Happened
A further $11.0 million milestone closing is tied to submission of a registrational Phase 3 PDS0301 protocol to the FDA, adding Capital to repay Debt and support late-stage development. As part of the transaction, NantWorks receives a one-year exclusive negotiation right for PDS0101, and Dr. Patrick Soon-Shiong joins the board.
Market Reaction
Shares rose sharply as investors responded to the new capital, the milestone-linked follow-on funding tied to the PDS0301 Phase 3 protocol, and the added credibility from Dr. Soon-Shiong's board appointment.
Outlook
Submission of the registrational Phase 3 PDS0301 protocol to the FDA, which would trigger the additional $11.0 million milestone closing, represents the next major disclosed step for PDS Biotechnology.
FAQs
Q: Why did PDS Biotechnology shares rise 35%?
A: Shares rose after the company completed the initial closing of an approximately $11.3 million PIPE led by Nant Capital.
Q: What triggers the additional $11.0 million milestone closing?
A: Submission of a registrational Phase 3 PDS0301 protocol to the FDA.
Q: What did NantWorks receive as part of the deal?
A: A one-year exclusive negotiation right for PDS0101, alongside Dr. Patrick Soon-Shiong joining PDS Biotechnology's board.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.